Awiqli® – the world’s first weekly basal insulin

Classified in: Health
Subject : New products and services

• Awiqli^® allows convenient intake once a week¹
• Health Approval Canada based on safety and efficacy data from the ONWARDS clinical trial program¹

MISSISSAUGA, ON, June 17, 2024 /CNW/ – Novo Nordisk is pleased to announce that the Canada will be the first country in the world to launch Awiqli^® (icodec insulin injection), which will be available nationally starting June 30, 2024. Awiqli^® is the world’s first weekly basal insulin and is indicated for the treatment of adults with diabetes mellitus to improve glycemic control¹. Health Canada approved Awiqli^® March 12, 2024¹.

“Awiqli^® represents a paradigm shift in diabetes care Canada and around the world,” said Dr. Richard Dumasendocrinologist at the CISSS Laval, director of the Clinical Research Center of Laval. “By moving from daily insulin injections to just one injection per week, Awiqli^® not only provides choice and convenience, but also ease for those who require basal insulin and need to begin treatment. »

Type 2 diabetes (T2D) is a progressive disease requiring intensification of treatment over time. Diabetes rates are increasing, leading to increased human and economic costs that impact individuals, communities, health care systems and societies².More than 4.1 million Canadians have diagnosed diabetes³ and may face the burden of daily injections^4,5. This can be a major barrier to adherence to insulin treatment in people with diabetes^4.5. Despite continued advances in diabetes treatments, there remains a significant gap in care, with half of adults with type 2 diabetes going undiagnosed and many unable to to achieve their glycemic goals^6.7.

“Diabetes continues to impact hundreds of thousands of people in Quebec, which explains why research and innovation play an essential role in supporting the management of diabetes,” said Sylvie Lauzon, president of Diabète Québec. “The availability of weekly basal insulin represents a paradigm shift in diabetes care, and we are excited about the potential of this new treatment for people affected by diabetes. »

Survey of Canadians with T2DM⁸

• The majority (58%) of Canadians surveyed with type 2 diabetes and taking insulin feel that controlling their diabetes with daily insulin injections is a burden, and 55% feel that taking daily insulin is difficult.
• More than three-quarters (77%) of Canadians surveyed with type 2 diabetes and taking insulin are interested in a solution allowing a less frequent administration schedule (than daily) and the majority (65%) want make their daily insulin routine easier.
• Likewise, more than half (57%) of people who do not take insulin would be in favor of insulin therapy if the doses were less frequent. Two in five people (43%) agree that daily insulin injections would not allow them to do what they love in life, e.g. e.g., travel more often.

AboutAwiqli^®
In March 2024, Novo Nordisk received regulatory approvals from Switzerland and Canada for once-weekly basal icodec insulin for the treatment of type 1 diabetes and type 2 diabetes in adults, followed by approval from the European Commission (EC) in May 2024.

In March 2024, Health Canada approved Awiqli^® (icodec insulin injection) as a once-weekly treatment for adults with diabetes mellitus to improve glycemic control based on data from the ONWARDS Phase 3a clinical trial¹. The ONWARDS Phase 3a trial program for weekly basal icodec insulin included six global Phase 3a clinical trials, including one real-world trial, involving more than 4,000 adults with type 2 or type 2 diabetes. 1. All trials met their primary endpoints¹.

Hypoglycemia (low blood sugar) is the most common side effect of all insulin preparations, including Awiqli.^®. The most commonly reported side effects include hypoglycemia, skin problems at the injection site, such as bruising, bleeding, pain or discomfort, redness, swelling or itching, and peripheral edema ( swelling, especially of the ankles and feet, caused by fluid retention¹).

About the T2DM survey⁸
Leger survey of 1,000 Canadians aged 18 or older with T2DM who are taking first-line treatments or taking insulin to manage their disease, or who have discussed insulin therapy with their healthcare professionals, but who have not started treatment. Conducted between April 23 and May 5, 2024, using Leger’s online panel. No margin of error can be associated with a non-random sample (i.e., a web panel in this case). However, for comparison, a random sample of 1,000 respondents would have a margin of error of ±3.1%, 19 times out of 20.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark. Our goal is to drive change to defeat serious chronic diseases, drawing on our extensive experience with diabetes. We do this by creating scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 63,400 people in 80 countries and markets its products in approximately 170 countries. For more information, visit novonordisk.ca, Facebook, Instagram, LinkedIn And Youtube.

SOURCE Novo Nordisk Canada Inc.

These press releases may also interest you at 08:01 Novo Nordisk is pleased to announce that Canada will be the first country in the world to launch Awiqli® (icodec insulin injection), which will be available nationally starting June 30, 2024. Awiqli® is the first basal insulin to take.. . at 08:01 Lenire, the first and only tinnitus treatment device of its kind approved by the FDA, is now an option for 2.9 million veterans living with tinnitus through Veterans Affairs.5Lenire is the first… . at 08:00 The allocation of scientific funds has not always been equitable. Historically, certain groups have been underfunded or marginalized, including researchers from Black communities,… at 07:00 Please note that the Honorable Patty Hajdu, Minister of Indigenous Services, will announce funding for the Weeneebayko Region Health Authority. She will be accompanied by the national head of the Assembly of First… at 07:00 Roger, now retired, worked for more than 40 years as a laborer in a construction company that manages small and large projects. He evolved in an environment including noisy machines, such as… at 06:00 Media representatives are invited to a press conference during which the Minister responsible for Social Services, Lionel Carmant, will make an announcement concerning the launch of a tool to promote and…

Press release sent on June 17, 2024 at 08:01 and distributed by: